Haag, G. M. and Zoernig, I. and Hassel, J. C. and Halama, N. and Dick, J. and Lang, N. and Podola, L. and Funk, J. and Ziegelmeier, C. and Juenger, S. and Bucur, M. and Umansky, L. and Falk, C. S. and Freitag, A. and Karapanagiotou-Schenkel, I. and Beckhove, P. and Enk, A. and Jaeger, D. (2018) Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. EUROPEAN JOURNAL OF CANCER, 90. pp. 122-129. ISSN 0959-8049, 1879-0852
Full text not available from this repository. (Request a copy)Abstract
Background: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. Patients and methods: Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks. Primary endpoint was the disease control rate (irCR, irPR or irSD) according to immune-related response criteria (irRC). Secondary endpoints included the disease control rate according to RECIST criteria, progression-free survival and overall survival (OS). Humoural and cellular immune responses against NY-ESO-1 were analysed from blood samples. Results: Disease control rate according to irRC was 52%, irPR was observed in 36% of patients. Progression-free survival according to irRC was 7.8 months, according to RECIST criteria it was 2.9 months. Median OS was 22.7 months; the corresponding 1-year survival rate was 66.8%. Treatment-related grade 3 AEs occurred in 36% with no grade 4-5 AEs. No clear association was found between the presence of NY-ESO-1-specific cellular or humoural immune responses and clinical activity. Conclusion: Ipilimumab demonstrated clinically relevant activity within this biomarker-defined population. NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade. (C) 2017 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | T-CELL RESPONSES; METASTATIC MELANOMA; CTLA-4 BLOCKADE; ANTIBODY; SURVIVAL; NIVOLUMAB; CANCER; Melanoma; Immunotherapy; Ipilimumab; Cancer/testis antigen; NY-ESO-1 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Regensburger Centrum für Interventionelle Immunologie (RCI) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Mar 2020 12:39 |
| Last Modified: | 20 Mar 2020 12:42 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15135 |
Actions (login required)
 |
View Item |
